Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$21.24 USD

21.24
1,162,460

+0.08 (0.38%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $21.23 -0.01 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

What Drives Catalyst Pharmaceuticals Above 250% This Year?

We take a look at the factors that drive phenomenal growth in Catalyst Pharmaceuticals' (CPRX) share price in 2017.

    Catalyst (CPRX) Reports Positive Phase III Data on Firdapse

    Catalyst (CPRX) reported encouraging top-line results from a phase III study for its pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome.

      Catalyst Initiates Phase II Study for Pipeline Drug Firdapse

      Catalyst (CPRX) announces the initiation of phase II study to evaluate safety, tolerability and efficacy of its lead pipeline candidate, Firdapse.

        Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3

        Catalyst Pharma (CPRX) remains focused on the development of its pipeline candidate firdapse in the third quarter of 2017.

          What's in Store for Catalyst (CPRX) This Earnings Season?

          Catalyst (CPRX) focus will be on pipeline and regulatory updates at the third-quarter earnings call.

            Catalyst (CPRX) Focused on Two Lead Pipeline Candidates

            : Catalyst (CPRX) remains focused on development of its two lead pipeline candidates, Firdapse and CPP-115.

              Catalyst (CPRX) Focused on Development of Pipeline Candidates

              Catalyst Pharmaceuticals, Inc. (CPRX) focuses on the development of its pipeline candidates Firdapse and CPP-115.

                Catalyst (CPRX) Posts Narrower than Expected Loss in Q2

                Catalyst Pharmaceuticals, Inc. (CPRX) reported narrower than expected loss in Q2 and is focused on the development of its pipeline candidate Firdapse.

                  What's in Store for Catalyst (CPRX) This Earnings Season?

                  With Catalyst Pharmaceuticals, Inc. (CPRX) not having any marketed product in its portfolio, its focus at the Q2 conference call will be on the progress of its pipeline candidates, Firdapse, CPP-115 and CPP-109.

                    Catalyst (CPRX) Shows Strength: Stock Adds 9.6% in Session

                    Catalyst Pharmaceuticals, Inc. (CPRX) shares rose around 10% in the last trading session.

                      Why is Catalyst Pharmaceuticals' Stock Up 160% this Year?

                      Shares of Catalyst Pharmaceuticals, Inc. (CPRX) have soared 161% this year so far, massively outperforming the Zacks classified Medical Drugs industry's gain of 10.2%.

                        Why Is Catalyst Pharmaceuticals (CPRX) Up 25.5% Since the Last Earnings Report?

                        Catalyst Pharmaceuticals (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                          Catalyst Pharmaceuticals (CPRX) Shares March Higher, Can It Continue?

                          As of late, it has definitely been a great time to be an investor in Catalyst Pharmaceuticals Inc (CPRX).

                            Catalyst Pharmaceuticals Focuses on Development of Firdapse

                            We issued an updated report on Catalyst Pharmaceuticals, Inc. (CPRX) on May 22.

                              Catalyst Pharmaceuticals (CPRX) Posts Loss as Expected in Q1

                              Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 6 cents per share in the first quarter of 2017, in line with the Zacks Consensus Estimate but narrower than the loss of 7 cents in the year-ago quarter.

                                What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?

                                Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report first-quarter 2017 results on May 11.

                                  Catalyst (CPRX) Up 16.6% Since Earnings Report: Can It Continue?

                                  Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                    Catalyst Pharmaceuticals (CPRX) Jumps: Stock Gains 18.2%

                                    Catalyst Pharmaceuticals, Inc. (CPRX) moved big last session, as its shares rose over 18% on the day.

                                      Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse

                                      We issued an updated research report on Catalyst Pharmaceuticals, Inc. (CPRX) on Mar 22.

                                        Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q4

                                        Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 5 cents per share in the fourth quarter of 2016, a penny narrower than the Zacks Consensus Estimate and also narrower than the loss of 7 cents in the year-ago quarter.

                                          Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?

                                          Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report fourth-quarter 2016 results this month.